Optimal Revascularization Time in Transient STEMI

Patients admitted with transient ST elevation MI and later normalize completely (symptimos disappear before being treated) are those we normally say are “undergoing a non-ST elevation MI”. This is complex, because revascularization time remains nuclear, as is whether to treat them as STEMI or non-STEMI patients.

The aim of this study was to determine the effects of an immediate strategy, compared against a differed strategy, quantifying infarct size with cardiac magnetic resonance.

 

The study randomized 142 patients with transient ST elevation MI to immediate (as if it were primary PCI in persistent STEMI patients) mean 0.3 hours vs. invasive differed strategy (as non-STEMI patients) with mean 22.7 hours.



Read also: The Ten Commandments for the Fourth Universal Definition of Infarction.


Infarction size measured by CMR at day 4 after the event was small and similar between strategies.

 

Neither were there differences in terms of major cardiac events, a combination of death, reinfarction or revascularization at 30 days (2.9% vs. 2.8%, p=1.00).


Read also: Are Aortic Stenosis and Kidney Dysfunction Associated?


Only 4 patients in the deferred group (5.6%) required emergency intervention given their signs and symptoms while waiting the angiography.

 

Conclusion

Globally, infarct size in patients presenting transient ST elevation MI is small and revascularization strategy, whether immediate or differed, has no influence. Hard events at short term were low and similar between the groups.

 

Original title: Timing of revascularization in patients with transient ST-segment elevation myocardial infarction: a randomized clinical trial.

Reference: Jorrit S. Lemkes et al. European Heart Journal (2019) 40, 283–291.

 

Infarto-elevacion-transitoria-st


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...